As Novartis Buys Into Gene Therapy, GSK Bows Out With Orchard Deal

Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market and has struggled to sell it, is asking out. The British pharma giant will send […] https://www.xconomy.com/boston/2018/04/12/as-novartis-buys-into-gene-therapy-gsk-bows-out-with-orchard-deal/

Eliminating Silos: Dismantling the Frankenstein of Clinical R&D

Clinical Informatics News Contributed Commentary In January 2017, there were 4,003 pharmaceutical companies with nearly 15,000 drugs in the pipeline. Yet only 1 in 5 drugs actually make it to market. Technology inherently aims to streamline processes, eliminate manual effort and create efficiencies, but is technology still doing this for clinical research?
 
 
 
 
http://www.clinicalinformaticsnews.com/2018/03/05/eliminating-silos-dismantling-frankenstein-clinical-rnd.aspx